Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
text
Tags
biotech
10
×
boston blog main
boston top stories
life sciences
national blog main
clinical trials
national top stories
san francisco blog main
boston
deals
san francisco top stories
cancer
cancer drugs
fda
new york blog main
new york top stories
startups
third rock ventures
blackstone group
david goldstein
depression
epilepsy
essential tremor
hepatitis b
investing
ipo
kiran reddy
major depressive disorder
perimenopausal depression
praxis precision medicines
revolution medicines
roche
san francisco
sanofi
steven petrou
the column group
venture capital
warp drive bio
abbvie
alexion pharmaceuticals
What
medicines
10
×
research
10
×
biotech
drug
drugs
new
cancer
ipo
aims
based
called
developing
disease
gene
genetic
praxis
precision
proteins
ready
revolution
stop
targets
therapeutics
way
abbvie
alderley
algorithms
alliance
amadeus
approach
backed
batch
biotechs
black
bottlenecks
cancer’s
capital
catapult
caught
cause
Language
unset
Current search:
medicines
×
research
×
biotech
×
@tech.eu
1 year ago
Amadeus Capital Partners’ Volker Hirsch joins Medicines Discovery Catapult as Chief Commercial Officer
@xconomy.com
3 years ago
Praxis Precision Medicines Leads Way as Three More Biotechs Prep IPOs
@xconomy.com
3 years ago
AbbVie Exits Editas Alliance, Pruning Another Genetic Medicines Pact
@xconomy.com
4 years ago
Backed by $100M, Praxis Aims to Turn Epilepsy Research Into New Neuro Drugs
@xconomy.com
4 years ago
Revolution Medicines IPO Reels In $238M to Take On RAS in Cancer
@xconomy.com
4 years ago
Revolution Medicines Maps Out an IPO to Reach Cancer’s Frontiers
@xconomy.com
4 years ago
Black Diamond Lines Up IPO as Lead Cancer Drug Nears Clinic
@xconomy.com
4 years ago
Roche to Pay Dicerna Pharma $200M to Team Up on Hepatitis B Drug
@xconomy.com
4 years ago
Flagship’s Omega Aims to Take Epigenetic Drugs a Step Further
@techcrunch.com
6 years ago
Reverie Labs uses new machine learning algorithms to fix drug development bottlenecks